Exercise and Asthma in Obese Adults

The primary aim of this pilot study is to recruit and retain obese adults with mild-moderate persistent asthma for a study protocol that includes exercise at a moderate intensity level in a home-based setting. The investigators primary hypothesis is that compared to no intervention, 12-weeks of moderate intensity aerobic exercise will attenuate serum levels of adipokines (leptin, adiponectin), and other pro-inflammatory markers. The investigators will also analyze the effect of the intervention on fitness levels, pulmonary function, asthma symptoms, asthma control, and asthma-related quality of life.

Given that this is a proof of concept/feasibility study, there is no primary outcome measure. The following measures will be assessed:

• Obesity related biomarkers and other markers of inflammatory responses:
• Asthma symptoms and asthma control measures:
• Lung function
• Fitness levels and physical activity levels:

Inclusion criteria

• Physician diagnosed asthma
• Currently prescribed a daily controller asthma medication as evidence of mild-moderate persistent asthma
• Body Mass Index BMI ≥ 30-45 kg/m2

Exclusion criteria

• Individuals who undergo aerobic exercise regularly (3 or more times per week for more than 20 minutes) 6 months prior to the study
• Participants with very severe obesity (WHO obese class III) - BMI≥ 45 kg/m2
• Individuals with other clinically significant major illnesses, such as congenital heart disease, juvenile arthritis, inflammatory bowel disease, cystic fibrosis, or other conditions that would limit participation in the exercise protocol or interfere with study measurements will not be eligible.
• Uncontrolled hypertension (resting systolic blood pressure > 150mmHg, and/or diastolic blood pressure >90 mmHg despite anti-hypertension medications.
• Current use of beta blockers
• Currently pregnant, pregnant during the previous six months, or planning to become pregnant in the next three months as obtained by self-report.
• Participants who have experienced a clinically significant exacerbation within the past 6 weeks will be excluded. This includes an unscheduled physician visit, emergency room visit, or hospitalization related or use of systemic corticosteroids for asthma.
• Unable or unwilling to provide consent
• Unable or unwilling to perform the exercise protocol and provide study measurements,
• Inability to perform baseline measurements
• Intend to move out of the area within 3 months from the start of the study
• Inability to be contacted by telephone